Therefore, the systemic inflammatory response in anti-MDA5 antibody-positive patients was more severe and had a poorer prognosis.[10,19,20] Consistent with the results of previous studies, our study demonstrated that patients positive for anti-MDA5 antibodies were more likely to develop ILD, lung infections, respiratory symptoms, arthralgia, and fever, and the inflammatory index ESR was relatively high compared to other types of antibodies. The gene discussed is IFIH1; the disease is interstitial lung disease.